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A B S T R A C T
The aim of this study was to determine whether hyperbaric oxygen (HBO2) treatment influences the expression of
transcriptional myogenic factors in denervated rat’s extensor digitorum longus muscle. Thus, expressing regulatory
myogenic factors MyoD and myogenin were analyzed in denervated muscles (up to 30 days). Second group of denervated
rats were afterwards treated with HBO2. Normal, innervated muscles were used as controls. Western blot analysis sho-
wed a significant upregulation of MyoD and myogenin proteins in denervated muscle during this period. Denervated
muscles of rats exposed to HBO2 treatment had also significant upregulation of both transcriptional factors but the treat-
ment had not altered their expression. The immunohistochemical analysis showed MyoD and myogenin protein expres-
sion through this period in the denervated, untreated muscles and in denervated muscles of rats treated with HBO2, too.
One month denervation caused a reduction in muscle fiber cross-sectional area. The treatment with HBO2 had not re-
duced the degree of atrophy. The protocol of hyperbaric oxygenation (HBO) applied in this study had no beneficial effect
either on transcriptional myogenic factors or on atrophy of denervated rat muscle.
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Introduction
Hyperbaric oxygen (HBO2) treatment is used as a pri-
mary therapy for many years in several medical condi-
tions and serves as an additional therapy to drugs and
other therapies for different disorders, especially those
caused by local hypoxia or ischemia. During HBO2 treat-
ment, the patient exposed to increased pressure, brea-
thes pure (100%) oxygen under pressure at a higher level
than the normal atmospheric pressure. That treatment
increases amount of oxygen dissolved in the plasma and
its delivery to the tissues. About forty percent of an
adult’s human body is comprised of skeletal muscles1.
The musculature is often susceptible to trauma and af-
fected by different diseases. HBO2 was shown to be bene-
ficial as an adjunctive treatment for ischemic muscles in
crush injuries, compartment syndrome and ischemia-re-
perfusion injuries2–8, although, in some studies HBO2
had no influence on healing9. The data about the effect of
hyperbaric oxygenation (HBO) on the healing of myoto-
xically damaged rat muscle10–12, or on the activity of met-
abolic enzymes differ. Effects of HBO on fiber types of
muscles from diabetic rats13, and healthy14–17 or young
rats18 are unequal, too. Some report of no effect, the others,
on the contrary found a beneficial effect of such treatment.
The regenerative capacity in adult skeletal muscles
depends on the capability of quiescent satellite cells to
proliferate, differentiate, and thus regenerate damaged
muscle tissue. Following injury, overloading, and exacer-
bated stretching, these cells become activated. During
this process, specific myogenic transcriptional factors are
up regulated in myogenesis. These transcriptional fac-
tors are myf5, MyoD, myogenin and MRF4. Inspite the
unequal results dealing with expression of myogenic
transcriptional factors in denervated muscles, in most of
the studies MyoD or myogenin expression was found to
be increased on transcriptional19,20 or protein level21–26.
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To our knowledge, as available from literature over-
view, the studies describing the influence of the HBO on
denervated muscle by itself have not been found (only as
an indicator of the function of crushed nerve treated
with HBO2). Thus, the aim of the present study was to
determine whether the HBO influences the degree of at-
rophy and expression of myogenic transcriptional factors
MyoD and myogenin in denervated rat extensor digito-
rum longus (EDL) muscle.
Material and Methods
Animals and experimental procedure
Male Sprague-Dawley rats weighing 200–250 g, used
in this study, were kept in standard cages at constant
temperature and given water and food ad libitum throu-
ghout the experimental period. The Ethics Committee of
the Medical Faculty of the University of Rijeka approved
the study. The animals were anaesthetized with an intra-
peritoneal injection of ketaminhydrochloride (0.1 mg/g
body weight) and xylazinhydrochloride (0.02 mg/g body
weight). Denervation was performed by removing a 5-mm
segment of the right sciatic nerve high in the thigh re-
gion. The proximal and the distal stump were ligated and
then sutured into surrounding muscles, far from each
other to prevent reinnervation. The denervated rats we-
re randomly divided in two main groups, denervated and
denervated hyperbaric group. After being operated, rats
in the denervated group received no further treatment
and were kept in cages until they were sacrificed after 3,
15 or 30 days of denervation. The animals of the experi-
mental hyperbaric group underwent HBO treatment af-
ter surgery and were placed in hyperbaric experimental
chamber in which pure oxygen was administered at 2.2
atmospheres absolute (ATA) pressure in a sixty-minute
session. Six rats were exposed at a time. The sessions
started on the day of operation and were conducted once
daily, always at the same time. The hyperbaric group was
also subdivided in three groups that matched to the
groups of denervated rats. The first and second group
was respectively treated for three or fifteen consecutive
days before being sacrificed. The rats in the third hy-
perbaric group were also exposed to the same hyperbaric
conditions for fifteen days, but were sacrificed thirty
days after denervation. Each group of animals consisted
of six rats. The oxygen concentration in the hyperbaric
chamber was kept 98.5% (Dräger Oxymeter). To elimi-
nate the accumulation of carbon dioxide chamber was
flushed with 100% oxygen at a rate of 4 L/min every 20
min during compression. Sodium carbonate crystals were
used to reduce the accumulation of CO2. All rats were
killed by the ether inhalation. The denervated extensor
digitorum longus (EDL) muscle was removed and qui-
ckly frozen in isopentane cooled by liquid nitrogen. The
EDL muscles of normal, innervated unoperated rats ser-
ved as controls to the experimental muscles, that is
denervated and denervated hyperbaric muscles. The mu-
scles were stored at –80 °C until further analysis. For
histological analysis, serial 8 mm-thick transverse sections
were cut and stained with haematoxylin and eosin (HE).
Protein extraction and western blotting procedures
For MyoD and myogenin immunoblotting, the total
muscle protein containing cytoplasmatic and nuclear fra-
ctions was extracted from EDL muscles by pulverization
of frozen samples. The samples were immersed in a ho-
mogenizing buffer containing 1% Nonidet P-40, 0.5% so-
dium deoxycholate, and 0.1% SDS in PBS. 0.1mM phe-
nylmethylsulfonylfluoride was added at the time of use
at 4 °C. The samples were incubated for 30 min at 4 °C.
Each homogenate was transferred to microfuge tubes
and centrifuged at 13000 rpm for 20 min at 4 °C, and the
supernatant was obtained. An aliquot of the supernatant
was used to determine the protein concentration using
Bredford method, and the remainder of the supernatant
was stored at –80 °C for subsequent Western blotting.
Optimal loading concentration for immunoblotting was
found to be 85 mg and 75 mg per sample for MyoD and
myogenin, respectively. Equal loading of samples was
comfirmed by comparison with a glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) immunoblot. To verify
MyoD and myogenin protein bands two control stan-
dards were run simultaneously in each gel: a molecular
weight marker (Precision Protein Standards); and pro-
tein isolated from neonatal rat muscles (highly express-
ing both myogenic regulatory factors). Proteins were
denaturated by boiling for 3 min after adding 5% solu-
tion for denaturation (500 mL Leammli, 25 mL 2-mercap-
toethanol). Proteins were separated in either a SDS-10%
(MyoD) or 12.5% (myogenin) polyacrylamide gel. The
proteins were transferred to nitrocellulose membranes
for 3 h at 70V. The membranes were immersed in block-
ing solution containing 0.5% nonfat dry milk (Bio-Rad),
dissolved in TBS (pH 7.46), for 1 h. Then the membranes
were incubated either with the monoclonal mouse anti-
-MyoD (1:400) (DakoCytomation) or monoclonal mouse
anti-myogenin (1:400) (DakoCytomation), diluted in blo-
cking solution overnight at 4 °C. After that, the mem-
branes were washed 6´10 min in TBS with 0.1% Tween
20 and incubated for 1 h at room temperature with a sec-
ondary antibody (rabbit anti mouse conjugated with pe-
roxidase 1:2000) (DakoCytomation). Then the membra-
nes were washed for five times with TBS with 0.1%
Tween 20 for 1 h. The antibody bindings were visualized
with DAB (diaminobenzidin, 0.1mg/ml), 0.02% hydrogen
peroxide and 0.03% CoCl. The quantity of blotted pro-
teins was evaluated by scanning densitometry.
Immunohistochemistry
For the MyoD and myogenin, the slides were fixed in
2% paraformaldehyde for 10 min, washed in TBS, and
treated with 3% H2O2 in TBS with 0.1% Tween 20
(TBST) for 5 min. Then the cryosections were washed in
TBS for 5 min. After that the slides were immersed in
blocking solution (10% normal swine serum in TBS with
0.2% bovine serum albumin – TBSTB) for 20 min. After-
wards, the slides were incubated for 60 min with the pri-
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mary mouse monoclonal antibody anti-MyoD (DakoCyto-
mation) or primary mouse monoclonal antibody anti-
-myogenin (DakoCytomation) diluted 1:50 in TBST. The
sections were washed 2´5 min in TBST, treated with the
secondary biotinylated antibody for 15 min and with
streptavidin conjugated to peroxidase for 15 min (LSAB
+Kit, DakoCytomation, ready-to-use). Finally, the sec-
tions were washed in TBS, visualized with AEC (3-
-Amino-9-ethylcarbazole) staining kit or with DAB for 10
min. After rinsed in water, the sections were mounted in
glycerol gelatin medium.
Morphometry
Cross-sectional areas of muscle fibers from the mus-
cles of three groups of animals were analyzed, normal
innervated muscles, muscles denervated for 30 days and
muscles denervated for 30 days but treated with HBO2.
These areas were analyzed by a computer program for
quantitative analysis »ISSA« (VAMS, Zagreb, Croatia).
About 500–600 fibers were measured by outlining the
contours of fibers.
Statistics
Cross-sectional area of muscle fiber with standard de-
viation (SD) was calculated. The statistical evaluations
were performed by Student t-test at p<0.05 level of sig-
nificance. All data are expressed as means and SE. The
results within each group and between groups were com-
pared using a two-way analysis of variance and the
Tukey-Kramer multiple comparisons post hoc test. The
level of significance was set at p<0.05.
Results
Muscle morphology and fiber size
Myofibers of unoperated EDL muscle displayed char-
acteristic polygonal shape in transverse sections, stained
with haematoxylin and eosin. In one month denervated
muscles of the untreated and the HBO2 treated rats, the
reduction in the muscle fiber cross-sectional area was ob-
served. The fibers were irregularly shaped. In normal,
innervated EDL muscle, the mean cross-sectional area of
fibers was 1960.4±515 mm2 and in one month denervated
untreated muscle was 941.3±332 mm2. The degree of at-
rophy was 52% and was statistically significant (p<
0.001) comparing to the normal muscle. The mean cross-
-sectional area of muscle fibers from the one month ener-
vated but HBO2 treated muscles were even lower, i.e.
928.2±307 mm2, and was also statistically significant (p<
0.001) comparing to that of the normal muscle.
Western blot analysis
MyoD and myogenin proteins were not detectable in
normal innervated EDL muscle using Western blot anal-
ysis. However, this analysis showed a progressive in-
crease in MyoD and myogenin protein expression in the
denervated and untreated EDL muscle. The immuno-
reactive bands of both proteins were detected on the 3rd,
15th and 30th day after denervation. The highest level of
expression was observed on the 30th day for both, MyoD
and myogenin (Figure 1). As an in denervated EDL, the
bands of both proteins were detected on the 3rd, 15th and
30th day after denervation in denervated and HBO2 trea-
ted EDL muscle as well. The highest expression of both
myogenic factors was found on the 30th day after dener-
vation and the HBO2 treatment (Figure 2). There were
no significant differences in the MyoD and myogenin ex-
pression levels in the EDL muscles between the un-
treated denervated rats and the denervated, but HBO2
treated muscles.
Immunohistochemistry
The immunohistochemical method with anti-MyoD
and anti-myogenin antibodies applied on serial trans-
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Fig. 1. MyoD and myogenin expressions determined by Western
blot in denervated extensor digitorum longus (EDL) muscle of
untreated rats. a) The levels of MyoD protein expression in the
EDL muscles after 3, 15 and 30 days of denervation. The immu-
noreactive band of ~45kDa corresponded to the predicted molecu-
lar mass of the rat MyoD protein. b) The levels of myogenin pro-
tein expression in the EDL muscles after 3, 15 and 30 days of de-
nervation. The immunoreactive band of ~34kDa corresponded to
the predicted molecular mass of the rat myogenin protein. GAPDH
was used as a loading control. The density of each band was ex-
pressed relative to the background density (considered to be 1.0).
verse sections of non-denervated muscles has not shown
the expression of these proteins (Figure 3). On the con-
trary, the expression of both transcriptional factors was
demonstrated in the denervated muscles and the dener-
vated muscles of HBO2 treated EDL in all three different
periods after denervation (Figure 4).
Discussion and Conclusion
Skeletal muscle undergoes rapid atrophy in response
to denervation. Denervated muscle loses large percent of
its weight during the first several weeks of the dener-
vation25,27–31. Progressive diminishing of the mean cross-
-sectional areas of muscle fibers occurs32, although the
atrophy does not affect all fiber types equally24,33,34. In
our study, we have found that the one month denervation
caused a decline of the mean cross-sectional area of fibers
in EDL for 52%, but HBO treatments had not addition-
ally diminished the degree of atrophy. The findings of
some other studies investigating the effect of HBO2 on
the muscle fiber size showed that HBO2 has not influ-
enced the degree of muscle fiber atrophy of healthy old
mice17. Those animals were exposed to lower oxygen con-
centration and pressure (36% O2 at 1.25 ATA), but 6
hours lasting sessions through two weeks. The rate of fi-
ber size changes may depend on the pressure and dura-
tion of applied HBO exposure as demonstrated by Gre-
gorevic et al.10. They showed that the pressure of 2 ATA
in 90 minutes session during 14 days did not alter fiber
size in EDL rat muscle damaged with bupivacaine injec-
tion, but prolonged exposure (25 days) or augmented
pressure (3 ATA) improved the size and function of
muscle10. Although the applied pressure and duration in
the aforementioned study were within the range of val-
ues of the protocols used in clinical treatments, we wan-
ted to examine the effect of lower pressure exposure, i.e.
2.2 ATA, as the standard treatment pressures used in hu-
mans are in the range from 2–2.5 ATA. Oter et al.35 de-
termined the effect of various HBO pressure modalities
on the oxidative values of rat lung, brain and erythro-
cytes. They concluded that, although the inhalation of
pure oxygen, rather than pressure causes oxidative stress.
Oxidative stress in the range of HBO pressure from 2 to
2.5 ATA was relatively low as compared with that seen at
3 ATA35.
As in our previous study36, in this study we demon-
strated an increased expression of myogenin and MyoD
protein throughout the period of one month after dener-
vation using either immunohistochemistry or Western
blot analysis. Although the results of some other studies
about the appearance of MyoD and myogenin in dener-
vated muscles are uneven, our results are in concordance
with the results of the majority of them; the expression
of MyoD and myogenin mRNAs levels19–21,25,37 or their
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Fig. 2. MyoD and myogenin expressions determined by Western
blot in denervated extensor digitorum longus (EDL) muscle with
hyperbaric oxygen treatment. a) The levels of MyoD protein ex-
pression in the EDL muscles after 3, 15 and 30 days of dener-
vation. The immunoreactive band of ~45kDa corresponded to the
predicted molecular mass of the rat MyoD protein. b) The levels
of myogenin protein expression in the EDL muscles after 3, 15
and 30 days of denervation. The immunoreactive band of ~34kDa
corresponded to the predicted molecular mass of the rat myoge-
nin protein. GAPDH was used as a loading control. The density
of each band was expressed relative to the background density
(considered to be 1.0).
Fig. 3. Immunohistochemical demonstration of myogenin expre-
ssion in cross section of innervated extensor digitorum longus
(EDL) muscle. No positive nuclei. Original magnification: x400.
protein levels increased in early postdenervation days21,37
and remained elevated even during one20,25 or several
months37. In our previous study36 we showed that MyoD
and myogenin proteins were localized in a large number
of myonuclei and to a lesser extent in the nuclei of satel-
lite cells. These data are in agreement with the findings
of Hyatt et al.25 and of Ishido at al.26. The latter, explor-
ing only MyoD transcriptional factor at the protein level,
found its expression in myonuclei and in satellite cells as
well. They assumed its presence in myonuclei as possible
protection of muscle against apoptosis26. In denervated
fast muscles the levels of myogenin protein increased
first few days after the nerve was cut and so it remained
till the end of the first month when it began to decline
gradually, and was located only in the myonuclei23. Iden-
tical localization of MyoD transcriptional factor was also
confirmed in denervated tibialis anterior muscle within
one week after denervation22.
The goal of this study was to find out whether the in-
creased amount of dissolved oxygen in the blood caused
by HBO2 treatment can increase the expression of MyoD
and myogenin transcriptional myogenic factors. How-
ever, the HBO2 treatment applied in this study has not
altered the expression of both myogenic transcriptional
factors in denervated EDL muscle when compared to
that of the untreated denervated muscle. The under-
standing of signaling and regulatory processes involved
in achieving the effects of hyperbaric oxygenation is
incomplete38. As the hyperbaric oxygenation treatments
are beneficial in the adjunctive therapy of several ische-
mic conditions, many experiments were done to explain
the mechanisms underlying this efficiency. An improved
regeneration of ischemic limb muscle achieved during
the HBO2 treatment was confirmed by the increase in
myf5 and several growth factors2. Exploring the positive
effect of HBO2 treatment on wound healing in ischemic
limb, it was found that HBO increased bone marrow ni-
tric oxide and thereby augmented the release of endothe-
lial progenitor cells in the peripheral circulation that
contribute to the wound healing improving the ischemic
limb perfusion39. Similar findings showed that the HBO
stimulates the nitric oxide synthase (nNOS) activity and
therefore increases the perivascular nitric oxide syn-
thesis40. The main pathway for the satellite cell activa-
tion from quiescence involves the release of nitric oxide
(NO)41. Elevated partial pressure of oxygen during HBO
increases synthesis of NO, probably through stimulation
of nNOS40. Thus our presumption was that HBO could
lead to stronger satellite cell activity in the denervated
muscle and therefore improve muscle regeneration. As ex-
plained in the study of Thom et al.42 the mechanism by
which HBO2 stimulates stem/progenitor cells mobiliza-
tion to the peripheral circulation evolved in mice when the
protocol procedure was applied at 2.8 ATA pressure, but
when it was changed to 2.0 ATA, it caused only a nominal
effect42. Thus, we assume that the pressure of 2.2 ATA ap-
plied in our study, might not be sufficient to provoke
stronger activation of satellite cells in denervated muscle.
In conclusion, the protocol of HBO2 treatments ap-
plied in this study had not diminished the degree of atro-
phy of the denervated EDL muscle and had not altered
expression of transcriptional factors MyoD and myoge-
nin. Denervation is not such as an ischemic condition in
the beginning, but later a substantial percentage of capil-
laries degenerate43 and migration of satellite cells toward
capillaries and small vessels occurs44. In respect to afore
mentioned, we speculate that in the late period of dener-
vation the HBO2 treatment could eventually be benefi-
cial in bringing larger amounts of oxygen to the cell. But
on the other side, there are large appositions of collagen
between myofibres in the late phase of denervation44.
Thus the ability of HBO2 to enhance the collagen produ-
ction45 probably could deteriorate already bad condition
in long-term denervated muscle.
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Fig. 4. a) Immunohistochemical demonstration of myogenin ex-
pression in cross section of extensor digitorum longus (EDL) mu-
scle on the third day after denervation and hyperbaric oxygen trea-
tment. Note the myogenin positive nuclei. Original magnification:
x400.< b) Immunohistochemical demonstration of myogenin ex-
pression in cross section of extensor digitorum longus (EDL)
muscle on the third day after denervation and hyperbaric oxygen
treatment. Note the myogenin positive nuclei. Original magnifi-
cation: x1000.
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UTJECAJ HIPERBARI^NOG KISIKA NA MIOGENE TRANSKRIPCIJSKE FAKTORE U
DENERVIRANOM MI[I]U [TAKORA
S A @ E T A K
Svrha je ovog rada bila odrediti utjecaj tretmana hiperbari~nim kisikom na ekspresiju transkripcijskih miogenih
faktora u denerviranom m. extensor digitorum longus {takora. Regulacijski miogeni faktori MyoD i miogenin anali-
zirani su u mi{i}u koji je bio denerviran tijekom 30 dana bez tretmana s hiperbari~nim kisikom i u denerviranom
mi{i}u, ali tretiranom hiperbari~nim kisikom. Western blot analiza je pokazala signifikantno pove}anje MyoD i mio-
genin proteina u denerviranom mi{i}u tijekom cijelog perioda. U denerviranim mi{i}ima {takora koji su bili tretirani
hiperbari~nim kisikom tako|er je do{lo do poja~ane ekspresije obaju transkripcijskih faktora, no, hiperbari~ni tretmani
nisu promijenili njihovu ekspresiju. Imunohistokemijska analiza pokazuje ekspresiju MyoD i myogenin proteina kroz
ovaj period u denerviranom netretiranom mi{i}u, a tako|er i u denerviranom mi{i}u {takora tretiranih hiperbari~nim
kosikom. Denervacija koja je trajala mjesec dana, dovela je do smanjenja povr{ine popre~nog presjeka mi{i}nog vlakna,
a tretman hiperbari~nim kisikom nije smanjio stupanj te atrofije. Protokol tretmana hiperbari~nim kisikom primije-
njen u ovoj studiji nema povoljan utjecaj na transkripcijske miogene faktore i na atrofiju denerviranog mi{i}a u {takora.
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